tbuckley/cabot-search huggingface dataset:
Performance of the ‘4S rule’ to predict short-term outcomes in cancer outpatients with unsuspected pulmonary embolism
Authors: D.S. Pesántez Coronel, D. Muñoz Guglielmetti, F. Posch, C. Ay, M. Aramberri, M.D.C. Beato Zambrano, C. Font
Journal: Annals of Oncology (2019)
Neoadjuvant chemotherapy can eliminate the negative impact of postoperative infectious complications on recurrence in patients with esophageal cancer
Authors: K. Kano, T. Ogata, K. Komori, H. Watanabe, Y. Shimoda, Y. Kumazu, H. Fujikawa, T. Yamada, T. Oshima
Journal: Annals of Oncology (2019)
Spanish survey of treatment recommendations for elderly patients with glioblastoma
Authors: M Á Vaz Salgado, Á Rodríguez Sánchez, I. Fernandez Perez, T. Quintanar, M. Navarro Martin, M. Vieito Villar, J.M. Cano, S. Gonzalez, S. Ros, A. Herrero Ibañez, M.A. Ivars, M. Lloret, M. Alonso, I. Moya, R. Luque, M. Benavides, M. Gutiérrez Toribio, J. García-Gómez, J. Esteban Villarrubia, J. Torres Jimenez
Journal: Annals of Oncology (2019)
Biological difference of tumour mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study
Authors: Y. Kawamoto, Y. Nakamura, M. Ikeda, H. Bando, T. Esaki, M. Ueno, T. Nishina, Y. Kagawa, E. Oki, T. Denda, T. Mizukami, N. Takahashi, N. Okano, I. Miki, Y. Sakamoto, M.I. Lefterova, J.I. Odegaard, H. Taniguchi, C. Morizane, T. Yoshino
Journal: Annals of Oncology (2019)
Circulating PD-L1 levels vary across brain tumour entities and are oppositely linked to survival in glioblastoma and lower grade glioma patients
Authors: M. Mair, A. Ilhan-Mutlu, S. Pajenda, G. Widhalm, K. Dieckmann, J.A. Hainfellner, C. Marosi, L. Wagner, M. Preusser, A.S. Berghoff
Journal: Annals of Oncology (2019)
Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study
Authors: Pilar Garcia-Broncano, Luz Maria Medrano, Juan Berenguer, Oscar Brochado-Kith, Juan González-García, Ma Ángeles Jiménez-Sousa, Carmen Quereda, José Sanz, María Jesús Téllez, Laura Díaz, José Luis JIménez, Salvador Resino
Journal: Journal of Infection (2019)
Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer
Authors: Y. Hashimoto, S. Hijioka, Y. Hirooka, E. Ohno, T. Ioka, S. Kobayashi, T. Okusaka, Y. Maruki, J. Yashika, R. Ashida, J. Furuse, M. Ikeda, H. Kasuya, M. Tanaka, M. Ueno
Journal: Annals of Oncology (2019)
Trajectories of Cognitive Function Prior to Cancer Diagnosis: A Population-Based Study
Authors: Kimberly D van der Willik, Michael Hauptmann, Katarzyna Jóźwiak, Elisabeth J Vinke, Rikje Ruiter, Bruno H Stricker, Annette Compter, M Arfan Ikram, Sanne B Schagen
Journal: JNCI Journal of the National Cancer Institute (2019)

An emerging body of research suggests that noncentral nervous system cancer may negatively impact the brain apart from effects of cancer treatment. However, studies assessing cognitive function in newly diagnosed cancer patients cannot exclude selection bias and psychological effects of cancer diagnosis. To overcome these limitations, we investigated trajectories of cognitive function of patients before cancer diagnosis.Between 1989 and 2013, a total of 2059 participants from the population-based Rotterdam Study were diagnosed with noncentral nervous system cancer. Cognitive assessments were performed every 3 to 5 years using a neuropsychological battery. The general cognitive factor was composed of individual cognitive tests to assess global cognition. Using linear mixed models, we compared change in cognitive function of cancer case patients before diagnosis with cognitive change of age-matched cancer-free control subjects (1:2). In addition, we performed sensitivity analyses by discarding assessments of control subjects 5 years before the end of follow-up to exclude effects from potential undiagnosed cancer. All statistical tests were two-sided.The Word Learning Test immediate recall declined faster among case patients than among control subjects (-0.05, 95% confidence interval = -0.09 to -0.01 vs 0.01, 95% confidence interval = -0.01 to 0.03; P for difference = .003). However, this difference was not statistically significant in sensitivity analyses. Furthermore, no statistically significant differences were observed in change of other individual cognitive tests and of the general cognitive factor.In this study, we evaluated cognitive function in a large group of cancer patients prior to diagnosis, thereby excluding the psychological impact of cancer diagnosis and biased patient selection. In contrast to previous studies shortly after cancer diagnosis, we found no difference in change of cognitive function between cancer patients and control subjects.
Phase II study of olaparib in previously treated advanced solid tumours with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
Authors: D. Hyman, A. Hendifar, H. Cheol Chung, M. Maio, A. Leary, I. Spanggaard, J. Rhee, M. Marton, M. Chen, S. Krishnan, R. Shapira
Journal: Annals of Oncology (2019)
Basal subtype predicts poorer prognosis in younger, but not older, African-American women with breast cancer.
Authors: Keith Dookeran, Xuezhi Gao, Yu Wang, Karen Ferrer, Marin Sekosan, Rocio De La Torre, Wei Chang, Mohammed Khadir, George Roman, Barbara Lukaszczyk, Erika Radeke, Worta McCaskill-Stevens, Howard Zaren
Journal: Cancer Research (2007)

2510  Introduction:  Prior reports suggest that a higher prevalence of basal subtype (basal) tumors in younger African-American (AA) women with breast cancer, could contribute to their observed poorer prognosis. The aim of this study was to determine and compare the value of basal subtype as a prognostic marker in AA women   Methods:  Immunohistochemical surrogates for intrinsic subtype classification were applied to tumors from 280 consecutive AA women. Correlates were examined with logistic regression and were compared as odds ratios (OR) and 95% confidence intervals (CI), and survival was computed using the Kaplan-Meier method with log-rank test.  Results:  Overall subtype distribution was: luminal A (estrogen [ER+], &/or progesterone receptor [PR+], & human epidermal growth factor receptor-2 [HER2-]) = 58%; luminal B (ER+, &/or PR+, & HER2+) = 10%; basal (ER-, PR-, HER2-, cytokeratin 5/6+ &/or HER1+) = 20%; HER2+/ER- type (ER-, PR-, & HER2+) = 10%; and unclassified (negative for all 5 markers) = 1%. For 85 women   Conclusions:  This study demonstrates that basal-subtype predicts poorer prognosis in younger, but not older, AA women with breast cancer, and these findings have important treatment implications for both groups of women. This effect appears independent of stage and may partly explain survival disparity in younger AAs, and is consistent with prior reports.
Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours
Authors: J. Strauss, Y. Vugmeyster, M. Sznol, R.K. Pachynski, K. Trang, S. Chennoufi, J.L. Gulley
Journal: Annals of Oncology (2019)
A comprehensive model of genetic-features predicts outcome of personalized adjuvant treatment in resected EGFR-mutant stage II-IIIA NSCLC: Results from a phase III trial (CTONG 1104-ADJUVANT)
Authors: Y.-L. Wu, S.-Y. Liu, Q. Wang, W. Mao, L. Wu, Y. Shen, Y. Cheng, C. Chen, L. Xu, J. Wang, H.-X. Liu, H. Bao, Y.-D. Chen, X. Zhang, Z.-H. Chen, H.-H. Yan, J.-J. Yang, Y.W. Shao, Q. Zhou, W.-Z. Zhong
Journal: Annals of Oncology (2019)
Insights into the tumour immune microenvironment using tissue phenomics to drive cancer immunotherapy
Authors: M. Groher, J. Zimmermann, H. Musa, A. Ackermann, M. Surace, J. Rodriguez-Canales, M. Rebelatto, K. Steele, A. Kapil, N. Brieu, L. Rognoni, F. Segerer, A. Spitzmüller, T.-H. Tan, A. Schäpe, G. Schmidt
Journal: Annals of Oncology (2019)
Natural dendritic cell vaccinations generate immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
Authors: J. Creemers, H. Westdorp, I. van Oort, G. Schreibelt, M. Gorris, N. Mehra, M. Simons, A. de Goede, M. van Rossum, S. Croockewit, C. Figdor, J.A. Witjes, E. Aarntzen, R. Mus, M. Gotthardt, J. Barentsz, J. de Vries, W.R. Gerritsen
Journal: Annals of Oncology (2019)
Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumour (TGCT): Characterization of hepatic adverse reactions (ARs)
Authors: S. Bauer, J.H. Lewis, H. Gelderblom, M. van de Sande, S. Stacchiotti, J.H. Healey, W.D. Tap, A.J. Wagner, A Lopez Pousa, M. Druta, C.-C. Lin, H.A. Baba, A. Yver, D.E. Shuster, J. McGill, X. Gu, L.D. DeLeve
Journal: Annals of Oncology (2019)
DNA methylation profiles of angiosarcoma subtypes
Authors: M.E. Weidema, E. de Jong, C. Koelsche, I.M.E. Desar, M.H.S. Hillebrandt-Roeffen, W.T. van der Graaf, Y.M.H. Versleijen-Jonkers, A. Von Deimling, U.E. Flucke
Journal: Annals of Oncology (2019)
Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients.
Authors: Suzanne Trudel, Susan Lee, Christopher J. Kirk, Nashat Gabrail, Sagar Lonial, Luhua Wang, Robert Z Orlowski, Vishal Kukreti, A. Keith Stewart, Sundar Jagannath, Kevin T. McDonagh, Francis Buadi, Jeffrey A Zonder, Mark K Bennett
Journal: Blood (2009)
One in five doctors have experienced or witnessed sexual harassment in the past three years, survey finds
Authors: Abi Rimmer
Journal: BMJ (2019)

A fifth of doctors (21%) have experienced or witnessed sexual harassment in the workplace over the past three years, a survey conducted by Medscape has found.1

The survey received responses from 1316 doctors in the UK. Of those, 17% said that they had been sexually harassed by a patient. A further 3% said that they had been sexually harassed by a colleague and 4% said they had witnessed harassment taking place, either from a patient or a …
Psychosocial intervention for discontinuing benzodiazepine hypnotics in patients with chronic insomnia: A systematic review and meta-analysis
Authors: Yoshikazu Takaesu, Tomohiro Utsumi, Isa Okajima, Akiyoshi Shimura, Nozomu Kotorii, Kenichi Kuriyama, Hidehisa Yamashita, Masahiro Suzuki, Norio Watanabe, Kazuo Mishima
Journal: Sleep Medicine Reviews (2019)

Long-term benzodiazepine (BZD) use is not recommended in the treatment of chronic insomnia, and psychosocial interventions, particularly cognitive behavioral therapy for insomnia (CBT-I), are a potential treatment option for discontinuing BZDs. This systematic review and meta-analysis aimed to clarify whether psychosocial interventions are effective for discontinuing BZD hypnotics in patients with chronic insomnia. A literature search of major electronic databases was conducted up to July 2018. Two researchers independently selected relevant publications, extracted data, and evaluated methodological quality according to the Cochrane criteria. Eight randomized-controlled trials, all of which evaluated CBT-I, were included in this review, and meta-analyses were performed. The results indicated that short-term (≤3 mo) CBT-I plus gradual tapering was more effective than gradual tapering alone for discontinuing BZDs hypnotics (risk ratio: 1.68, 95% confidence interval [CI]: 1.19–2.39, p = 0.003) and for improving insomnia symptoms (g: −0.69, 95% CI: −1.09 – −0.28, p = 0.0009). However, the long-term (12 mo) efficacy of CBT-I for discontinuing BZDs was not significant (risk ratio: 1.67, 95% CI: 0.91–3.07, p = 0.10). Thus, CBT-I is effective for discontinuing BZD hypnotics for ≤3 mo. Further studies are needed to clarify the long-term efficacy of psychosocial interventions for discontinuing BZD hypnotics.
Complementary medicine (CM) use in phase III clinical trials (P3T) conducted by the Canadian Cancer Trials Group (CCTG)
Authors: J.C. Wells, A. Sidhu, K. Ding, D.Y.C. Heng, F. Shepherd, P.M. Ellis, P.A. Bradbury, D.J. Jonker, M. Moore, L.L. Siu, K.A. Gelmon, C. Karapetis, J. Shapiro, L. Nott, C.J. O’Callaghan, W.R. Parulekar, L.K. Seymour, M. Smoragiewicz, J.G. Monzon
Journal: Annals of Oncology (2019)
Exploring candidate signal transduction pathways for targeted therapy in esophageal cancer
Authors: A. Creemers, S.L. Meijer, L. Holtzer, M. Stoffels, H. van Ooijen, A.G.C. van Brussel, E.M.G. Aussems-Custers, M.I. van Berge Henegouwen, M. Hulshof, S.K. Krishnadath, A. van de Stolpe, M.F. Bijlsma, H.W.M. van Laarhoven
Journal: Annals of Oncology (2019)
Identifying falls-related variables and risk factors in hospitalised cancer patients
Authors: M.M. Martí Dillet, P. Fernandez, C. Fernández Rodríguez, A. Durán Adán, M. Codina Pons, R. Rodríguez Moreno, I. Conejero Inglés, I. Brao Pérez
Journal: Annals of Oncology (2019)
PB2014 INTERFERON-FREE ANTIVIRAL THERAPY IN THE TREATMENT OF RELAPSE HEPATITIS C VIRUS ASSOCIATED MARGINAL ZONE LYMPHOMA
Authors: S. Lepkov, I. Subortceva, G. Tumian, A. Lepkov, O. Kolomeitcev, J. Ribykhina, N. Kokosadze, N. Kuprichina, P. Zeynalova, S. Borisovskay, T. Padgeva, R. Ivashenco, N. Petrenco, V. Ivanova, I. Lazarev, O. Zaharov, O. Ettinger, I. Nikitin
Journal: HemaSphere (2019)

Background: The association between the hepatitis C virus (HCV) and B-cell non-Hodgkin lymphomas (NHL) confirmed by epidemiological and therapeutic data. Most common association found with marginal zone lymphoma (MZL) and chronic HCV infection. A large number of studies have demonstrated that antiviral therapy (AT) with interferon (IFN) and ribavirin (RBV) can cause a high frequency of remission in HCV-associated indolent B-cell NHL. However, there were limited data about anti-tumor activity of the new direct-acting antiviral agents (DAAs) in the treatment of HCV+ MZL. Aims: The aim of our report is the description of 2 patients HCV+ MZL, relapsed after IFN therapy and successful treated with DAAs. Methods: 31 patients (pts) with HCV+ MZL treated by IFN + RBV as the first-line therapy from 2005-2018. Median follow-up was 52 months. The relapse of lymphoma developed in 6 pts (19%), median duration of response was 38 months. We observed 2 women 41 and 58 years that had HCV infection (genotype 1b) more than 120 months before the clinical manifestation of lymphoma. The first patient had splenic MZL, the second patient diagnosed of disseminated variant with multiple nodal and extranodal (bone marrow, orbit, liver, soft tissue) involvement. IHC detected HCV protein expression on the tumor cells. Lymphoma and HCV remission achieved on 6- and 8-months INF+RBV therapy. The treatment interrupted after 24 and 28 months due to adverse events (fewer, redness, rash and swelling of the injection site). Blood examination was detected of neutralizing antibodies to interferon. After the end of the treatment the patients had a relapse of lymphoma on 18 and 23 months Results: At that time the remission of HCV continued. Re-biopsy were confirmed MZL, ICH again detected HCV protein expression on the tumor cells of both patients, in the blood neutralizing antibodies to interferon were present. Patients were treated with «interferon-free» antiviral regimen: ledipasvir 90 mg and sofosbuvir 90 mg per day. MZL complete remission achieved after 3 and 5 months of therapy. Antiviral therapy was continued 6 and 8 months. Summary/Conclusion: Conclusion: Antiviral therapy is the preferred first-line option in patients with HCV-associated MZL. The use of new direct-acting antiviral agents is effective in the relapse of the disease. However, the duration of antiviral therapy should be 6 months or longer but these data require further study.
Investigation of the reclassification of G1/G2 pancreatic neuroendocrine neoplasms by WHO 2017 classification
Authors: T. Yokose, M. Kitago, M. Shinoda, H. Yagi, Y. Abe, G. Oshima, S. Hori, Y. Endo, K. Hayashi, Y. Kitagawa
Journal: Annals of Oncology (2019)
Identification of Distant Metastases From Recurrent Gliosarcoma Using Whole-Body 18F-FDG PET/CT
Authors: Marcus Unterrainer, Viktoria Ruf, Clemens C. Cyran, Matthias Brendel, Niklas Thon, Jochen Herms, Ulrich Schüller, Joerg-Christian Tonn, Peter Bartenstein, Nathalie Lisa Albert
Journal: Clinical Nuclear Medicine (2019)

A 51-year-old man presented with recurrent gliosarcoma and increasing cough over the last months. On F-FDG PET/CT, solid lung masses with high F-FDG uptake were present. A biopsy taken from a lung lesion indicated distant metastases from gliosarcoma. Gliosarcoma, a rare malignant central nervous system tumor, presents with extracranial metastases in only less than 10%. As highlighted by this case, F-FDG PET/CT can be used for whole-body staging in patients with metastatic brain tumor. Vice versa, highly F-FDG-avid lung lesions in patients with brain tumors should lead to distant metastases as differential diagnosis despite their rare occurrence.
Polymorphisms in the DNA repair gene XRCC1 and survival of non-small cell lung cancer
Authors: S. M. Yoon, H. J. Park, S. Y. Kim, J. H. Kim, S. S. Shin, Y.-C. Hong, S.-Y. Park, J. E. Lee, E. K. Choi
Journal: Journal of Clinical Oncology (2005)

9585 Background: X-ray cross-complementing group 1 (XRCC1) protein is known to be mainly involved in BER(base excision repair) of DNA repair process. We investigated the association of three polymorphisms (codon 194, 280, and 399) of XRCC1 with lung cancer, whether these polymorphisms have an effect on survival of lung cancer patients received radiotherapy. Methods: 229 lung cancer patients with NSCLC in stage I-IV were recruited at Asan Medical Center and followed up at least every 3 months from the time of study entry. Genotyping was performed by single base primer exclusion assay using SNapShot Kit with blood samples from all patients. Kaplan-Meier survival curve was used for polymorphism effect on progression-free and overall survival. Hazard ratio by Cox-proportional hazard regression was calculated after adjustment for age, gender, histology, stage, and alcohol consumption. These variables were selected through the univariate analysis performed previously. The haplotype of XRCC1 polymorphisms was estimated by PHASE version 2.1. Results: The subjects were consisted of 191(83.4%) males and 38(16.6%) females. The median age was 62 (range 26 - 88) and 60% of patients were included in stage I-IIIa. More than 85% of patients had squamous cell carcinoma and adenocarcinoma. The mean survival time was 20.2 months and 22.5 months in progression-free and overall survival, respectively. XRCC1 codon 194, histology, and stage were shown to be a significant predictor in progression-free survival and alcohol consumption seemed to have protective effect significantly (p=0.028). The six haplotypes among XRCC1 polymorphisms (194, 280, and 399) were estimated by PHASE v.2.1. The patients with the haplotype pairs other than homozygous TGG haplotype pairs seemed to survive longer significantly compared with those with them (p=0.04). Conclusions: In the present study, we suggest that polymorphisms of XRCC1 have an effect on survival of lung cancer patients treated with radiotherapy and the effect appears more strongly considering haplotype pairs. No significant financial relationships to disclose.
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia
Authors: Beatrice Del Papa, Stefano Baldoni, Erica Dorillo, Filomena De Falco, Chiara Rompietti, Debora Cecchini, Maria Grazia Cantelmi, Daniele Sorcini, Manuel Nogarotto, Francesco Maria Adamo, Federica Mezzasoma, Estevão Carlos Silva Barcelos, Elisa Albi, Roberta Iacucci Ostini, Ambra Di Tommaso, Andrea Marra, Guido Montanaro, Maria Paola Martelli, Franca Falzetti, Mauro Di Ianni, Emanuela Rosati, Paolo Sportoletti
Journal: Clinical Cancer Research (2019)

Ibrutinib, a Bruton tyrosine kinase inhibitor (BTKi), has improved the outcomes of chronic lymphocytic leukemia (CLL), but primary resistance or relapse are issues of increasing significance. While the predominant mechanism of action of BTKi is the B-cell receptor (BCR) blockade, many off-target effects are unknown. We investigated potential interactions between BCR pathway and NOTCH1 activity in ibrutinib-treated CLL to identify new mechanisms of therapy resistance and markers to monitor disease response.NOTCH activations was evaluated either in vitro and ex vivo in CLL samples after ibrutinib treatment by Western blotting. Confocal proximity ligation assay (PLA) experiments and analyses of down-targets of NOTCH1 by qRT-PCR were used to investigate the cross-talk between BTK and NOTCH1.In vitro ibrutinib treatment of CLL significantly reduced activated NOTCH1/2 and induced dephosphorylation of eIF4E, a NOTCH target in CLL. BCR stimulation increased the expression of activated NOTCH1 that accumulated in the nucleus leading to HES1, DTX1, and c-MYC transcription. Results of in situ PLA experiments revealed the presence of NOTCH1-ICD/BTK complexes, whose number was reduced after ibrutinib treatment. In ibrutinib-treated CLL patients, leukemic cells showed NOTCH1 activity downregulation that deepened over time. The NOTCH1 signaling was restored at relapse and remained activated in ibrutinib-resistant CLL cells.We demonstrated a strong clinical activity of ibrutinib in a real-life context. The ibrutinib clinical efficacy was associated with NOTCH1 activity downregulation that deepened over time. Our data point to NOTCH1 as a new molecular partner in BCR signaling with potential to further improve CLL-targeted treatments.
Clinical Significance of Small Intestinal Involvement Detected by Double-Balloon Enteroscopy In Patients with Non-Hodgkin's Lymphoma
Authors: Hisashi Tsurumi, Takashi Ibuka, Takeshi Hara, Hiroshi Araki, Soranobu Ninomiya, Naoe Goto, Humito Onogi, Nobuhiro Kanemura, Senji Kasahara, Tomohiro Kato, Tsuyoshi Takami, Hisataka Moriwaki
Journal: Blood (2010)
Achieving best possible cancer treatment outcomes in care pathways through benchmarking; ABC-Benchmarking
Authors: A. Wind, M. Bessems, R.R. van Eekeren, C.J. Wijburg, J. Mattson, J. Halamkova, M. Svoboda, J. Oliveira, J Abreu de Sousa, W.H. van Harten
Journal: Annals of Oncology (2019)